In women with newly diagnosed breast cancer without diabetes, adding metformin to adjuvant therapy has been shown to decrease IGF-1, ratio of IGF-1 to IGFBP-3, insulin, fasting blood glucose, and HOMA-IR [150]. The gene discussed is INS; the disease is breast carcinoma.